Bicara Therapeutics Inc.
BCAX
$24.28
$0.652.75%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -80.54% | -70.38% | -102.88% | -104.31% | -58.34% |
| Total Depreciation and Amortization | 127.94% | 109.68% | 87.50% | 40.00% | 61.90% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 96.25% | 96.78% | 121.34% | 140.44% | -30.28% |
| Change in Net Operating Assets | 346.33% | 483.90% | 204.79% | -797.40% | -1,066.24% |
| Cash from Operations | -33.57% | -31.68% | -42.92% | -114.16% | -119.17% |
| Capital Expenditure | -733.33% | -407.46% | -294.37% | 82.44% | 92.12% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -100.00% | -100.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -838,445.83% | -324,546.27% | -3,538,266.67% | -58,211.36% | 91.22% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -40.94% | -41.80% | -90.37% | -99.69% | 21,443.13% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 200.00% |
| Cash from Financing | -40.87% | -41.63% | -90.34% | -99.99% | 41.74% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -246.08% | -156.34% | -251.59% | -173.25% | 23.24% |